| ADE: | adverse drug effect |
| AFS: | aryl-fluorosulfate (aryl-OSO2F) |
| bioTCI: | biomolecular targeted covalent inhibitor |
| CD: | cluster of differentiation |
| CHO: | Chinese hamster ovary |
| CS: | complimentary strand |
| CuAAC: | copper(I)-catalyzed azide-alkyne cycloaddition |
| Da: | Dalton |
| DS: | double strand |
| EdUTP: | 5-ethynyl-dUTP |
| EGFR: | epidermal growth factor receptor |
| ELISA: | enzyme-linked immunosorbent assay |
| Fab: | fragment antigen binding (variable) |
| FasL: | Fas ligand (CD95L, CD178) |
| Fc: | fragment crystallizable (constant) |
| FcR: | Fc receptor |
| FDA: | Food and Drug Administration (USA |
| GPCR: | G-protein-coupled receptor |
| HER2: | human epidermal growth factor 2 |
| mAb: | monoclonal antibody |
| NK: | natural killer |
| NGS: | next-generation sequencing |
| OctdU: | octadiynyl-dU |
| PCR: | polymerase chain reaction |
| PD1: | programmed cell death protein 1 (CD279) |
| PD-L1: | programmed death-ligand 1 (CD274) |
| PK: | pharmacokinetic |
| PPI: | protein-protein interaction |
| PS: | phosphorothioate |
| RBD: | receptor binding domain |
| SARS-CoV-2: | severe acute respiratory syndrome-associated coronavirus-2 |
| SELEX: | Systematic Evolution of Ligands by EXponential enrichment |
| SN2: | bimolecular nucleophilic substitution |
| SNAr: | nucleophilic aromatic substitution |
| SuFEx: | sulfur (VI) fluoride exchange |
| SDS: | sodium dodecyl sulfate |
| TBA: | thrombin binding aptamer |
| TCI: | targeted covalent inhibitor |
| TeTCI: | tethered targeted covalent inhibitor |
| TRAIL: | TNF-related apoptosis-inducing ligand |
| Uaa: | unnatural amino acid |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.